Synektik

Synektik EBIT Growth

The Year-over-Year EBIT Growth of Synektik (SNT.WA) as of Nov 3, 2026 is 46.83 %. In the previous year, Year-over-Year EBIT Growth was 57.59 % — a change of -18.68% (lower).

EBIT Growth

46.83 %

YoY

-18.68%

Last updated:

Year-over-Year EBIT Growth of Synektik is 2025 46.83 % . Year-over-Year EBIT Growth of Synektik was 2024 57.59 % . It decreases by -18.68% lower compared to the previous year.

The Synektik EBIT Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Growth
Date
EBIT Growth
Jan 1, 2018
225.39 PLN
Jan 1, 2019
9.32 PLN
Jan 1, 2020
-5.38 PLN
Jan 1, 2021
-7.02 PLN
Jan 1, 2022
-37.08 PLN
Jan 1, 2023
864.11 PLN
Jan 1, 2024
57.59 PLN
Jan 1, 2025
46.83 PLN
The Synektik EBIT Growth history
YEAREBIT GrowthYoY
46.83 %-18.68%
57.59 %-93.34%
864.11 %-2,430.33%
-37.08 %+428.44%
-7.02 %+30.51%
-5.38 %-157.70%
9.32 %-95.87%
225.39 %+231.59%
67.97 %-85.66%
473.86 %-528.67%
-110.54 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Synektik Stock analysis

What does Synektik do? Synektik SA generates revenue through its PACS software, which enables diagnostic imaging laboratories to operate efficiently. The company also sells medical equipment and provides services through its imaging equipment services center. Synektik SA partners with Siemens and holds a 100% stake in Miedzynarodowe Centra Medyczne Inwestycje Sp z o o, which it acquired by raising its stake on November 28, 2013. The firm's research laboratory conducts acceptance and specialist tests on X-ray equipment, contributing to its service offerings. The primary buyers of Synektik SA's products include diagnostic imaging laboratories that require PACS software for their operations. Medical equipment is sold to healthcare facilities, while the research laboratory services are utilized by entities needing X-ray equipment testing. The company's partnership with Siemens supports its medical equipment sales and services. Synektik SA's revenue streams are derived from software licensing, medical equipment sales, and specialized testing services. The company's focus on diagnostic imaging solutions and its ownership of Miedzynarodowe Centra Medyczne Inwestycje Sp z o o position it within the medical technology sector, targeting healthcare providers and imaging laboratories. Synektik is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Synektik stock

Year-over-Year EBIT Growth of Synektik is 46.83 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year EBIT Growth Synektik since 2006 – with annual values, charts, and detailed analysis.

EBIT growth measures the percentage change in operating earnings. It shows whether a company's core operations are becoming more profitable.

To evaluate Year-over-Year EBIT Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBIT Growth.

Year-over-Year EBIT Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBIT Growth's Synektik historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Growth — Synektik

Revenue GrowthRevenue CAGR 3YRevenue CAGR 5YRevenue CAGR 10YEarnings GrowthEPS GrowthEBIT GrowthEBIT CAGR 3YEBIT CAGR 5YEBIT CAGR 10YDividend GrowthFCF GrowthBook Value GrowthEarnings CAGR 3YEarnings CAGR 5YEarnings CAGR 10YEPS CAGR 3YEPS CAGR 5YEBITDA Growth YoYEBITDA CAGR 3YEBITDA CAGR 5YGross Profit GrowthOCF Growth YoYEmployee GrowthDividend CAGR 3YDividend CAGR 5YDividend CAGR 10YAsset GrowthEquity GrowthDebt GrowthCapEx GrowthFCF CAGR 3YFCF CAGR 5YMarket Cap GrowthShare Count Growth

All Key Metrics — Synektik